Evidence-Based Summary
Glucagon-like peptide-1 (GLP-1) and peptide tyrosine tyrosine (Peptide YY, or PYY) are the two signature gastrointestinal hormones synthesized, stored in identical secretory granules, and co-released by enteroendocrine L-cells in the distal ileum and colon upon nutrient ingestion. When digested fats and carbohydrates reach the lower small intestine, L-cells release both peptides into the mesenteric circulation to signal the 'ileal brake', a coordinated feedback loop that slows gastrointestinal motility and signals meal termination. However, their cellular targets and intracellular mechanisms are completely distinct. GLP-1 acts primarily as an incretin hormone via class B1 GPCRs (GLP-1R) coupled to Gαs, elevating cAMP in pancreatic beta cells to stimulate insulin secretion while suppressing glucagon and signaling satiety. Peptide YY, specifically its active circulating metabolite PYY(3-36) generated by DPP-4 cleavage, acts as a pure neuroendocrine satiety mediator via class A GPCRs (specifically the neuropeptide Y receptor Y2 subtype, NPY2R) coupled to Gαi. By activating presynaptic inhibitory Y2 auto-receptors in the hypothalamic arcuate nucleus, PYY(3-36) suppresses orexigenic NPY/AgRP neurons and disinhibits anorexigenic POMC neurons. While GLP-1 analogues are used to treat obesity and diabetes, PYY analogues have historically faced challenges with severe nausea at therapeutic doses, leading to current clinical development focused on combined dual GLP-1/PYY co-agonists.
Quick Comparison: GLP-1 vs Peptide YY (PYY)
A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.
| Feature | GLP-1 | Peptide YY (PYY) |
|---|---|---|
| Biological classification | Incretin & satiety peptide hormone | Neuroendocrine satiety peptide hormone |
| Cellular origin | Enteroendocrine L-cells (distal gut) | Enteroendocrine L-cells (co-stored in same granules) |
| Primary receptor target | GLP-1 receptor (Gαs-coupled, elevates cAMP) | Neuropeptide Y receptor subtype 2 (Y2R, Gαi-coupled) |
| Circulating active form | GLP-1(7-36)amide (cleaved into inactive form by DPP-4) | PYY(3-36) (activated by DPP-4 cleavage from PYY[1-36]) |
| Beta-cell insulin stimulation | Potent glucose-dependent stimulation | No direct insulinotropic effect |
| Appetite regulation mechanism | POMC activation + vagal afferent nerve signaling | Presynaptic Y2R inhibition of NPY/AgRP neurons |
| Gastric emptying effect | Potently decelerates gastric emptying | Contributes to the 'ileal brake' slowing motility |
| Clinical drug translation | Dozens of approved drugs (Semaglutide, Liraglutide) | Investigational dual co-agonists in clinical trials |
Gαs/cAMP vs Gαi/NPY2R Receptor Cascades
How two peptides from the same gut cell activate different branches of the appetite regulatory network.
GLP-1: Incretin Stimulation & Arcuate POMC Activation
Primary Target: GLP-1 Receptor (GLP-1R)
Affinity Profile: Class B GPCR; couples to Gαs and beta-arrestin
GLP-1 binds to GLP-1R on vagal sensory nerve terminals and circumventricular brainstem/hypothalamic centers. It elevates cAMP, activating PKA and directly depolarizing POMC/CART neurons, which release alpha-MSH to stimulate MC4 receptors and induce satiety.
PYY(3-36): Presynaptic Y2 Auto-Receptor Inhibition
Primary Targets: Neuropeptide Y Y2 Receptor (NPY2R)
Affinity Profile: High selectivity for Y2 subtype (Kd ~0.1 nM)
Cleaved by DPP-4 to remove Tyr1-Pro2, PYY(3-36) crosses the fenestrated capillaries of the median eminence to access the arcuate nucleus. It binds to presynaptic Y2 receptors on orexigenic NPY/AgRP neurons, activating Gαi to inhibit adenylate cyclase and reduce calcium influx. This suppresses hunger peptide release and disinhibits adjacent POMC neurons.
Therapeutic Translation & Drug Pipeline
GLP-1 has yielded blockbuster commercial medicines; PYY remains a major frontier in investigational obesity pharmacotherapy.
GLP-1 Status & Formulations
Not approved by the FDA or EMA for human clinical use.
Peptide YY (PYY) Status & Formulations
Not approved by the FDA or EMA for human clinical use.
Critical Regulatory Distinction
Multiple pharmaceutical firms are developing long-acting PYY3-36 analogues and dual GLP-1/PYY co-agonists (such as NN9748) to capture the additive weight-loss synergy observed following bariatric Roux-en-Y gastric bypass.
Infusion Studies & Bariatric Surgery Physiology
Co-infusion studies demonstrate that GLP-1 and PYY act additively to reduce caloric intake in humans.
GLP-1: Neary et al. Landmark Co-Infusion RCT
In a landmark double-blind crossover study (Endocrinology 2005), co-infusing sub-anorectic doses of GLP-1 and PYY(3-36) in human volunteers reduced ad libitum energy intake by 27%, a significantly greater reduction than either hormone alone (GLP-1 alone -15%, PYY alone -15%), demonstrating true synergistic satiety.
Peptide YY (PYY): Bariatric Surgery Endocrine Profile
Following Roux-en-Y gastric bypass (RYGB), circulating postprandial concentrations of both GLP-1 and PYY increase by 500% to 1,000% within days of surgery, driving sustained postoperative appetite reduction and weight loss.
Nausea Hurdles in PYY Drug Development
Why single-agent PYY therapies faced historical clinical development hurdles.
| Safety Consideration | GLP-1 | Peptide YY (PYY) |
|---|---|---|
| Therapeutic window | Broad; nausea manageable with gradual dose ramp | Narrow; high doses trigger rapid, intense nausea and emesis |
| Cardiovascular effects | Slight increase in resting heart rate (+1 to 3 bpm) | Y2 agonism causes minimal heart rate alterations |
What GLP-1 and Peptide YY (PYY) Have in Common
Where the two compounds overlap in biology, evidence or regulatory context.
Co-Secretion Origin
Both hormones are packaged within the same dense core secretory granules of enteroendocrine L-cells.
Satiety Mediation
Both peptides act on the central nervous system to reduce appetite and terminate food consumption.
Key Scientific & Clinical Differences
Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.
Incretin Activity
GLP-1 is a potent glucose-dependent insulin secretagogue; PYY has no direct insulinotropic effect.
DPP-4 Processing
DPP-4 inactivates GLP-1, but DPP-4 ACTIVATES PYY by converting PYY(1-36) into the selective Y2-agonist PYY(3-36).
Approved Medications
GLP-1 has dozens of FDA-approved medicines; PYY has zero approved monotherapies to date.
Scientific Comparison vs Clinical Recommendations
Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.
Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.
Approved Uses vs Online Claims
A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.
PYY peptide injections will replace Ozempic as the best weight loss drug
insufficientNo PYY peptide is FDA approved; clinical development remains investigational.
Single-agent PYY causes narrow therapeutic window issues (emetic response). Modern drug development focuses on combining low-dose PYY with GLP-1 to harness synergy without nausea.
Evidence Strength Across Clinical Domains
Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.
Satiety & Caloric Intake Reduction
Both hormones proven in human infusion trials to significantly diminish food consumption.
Incretin Glucose Control
GLP-1 is a validated incretin; PYY has no direct glycemic lowering role.
What Research Still Doesn’t Tell Us
Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.
Subcutaneous Long-Acting PYY Pharmacokinetics
Achieving smooth, non-emetic 7-day pharmacokinetic release of Y2-selective agonists in human clinical trials.
Related Compound Profiles
Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.
Related Educational Resources
Scientific & Regulatory References
Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.
-
Peer-Reviewed RCT
Peptide YY3-36 and glucagon-like peptide-1(7-36) inhibit food intake additively
-
Peer-Reviewed Article
Gut hormone PYY3-36 physiologically inhibits food intake